Skip to main content
Premium Trial:

Request an Annual Quote

Two New RNAi-Related Patent Application Published By US Patent Office


Title: Treatment of Melanoma by Reduction in Clusterin Levels. Number: 20040082534. Filed: Aug. 21, 2003. Lead Inventor: Martin Gleave, Vancouver General Hospital.

The patent application, its abstract states, covers the treatment of melanoma through “reduction in the effective amount of clusterin in melanoma cells … in a mammalian subject, preferably a human.”

The abstract states that “the therapeutics agent may be … a small inhibitory RNA [compound] targeted to clusterin. Bcl-xL in a subject or cell line can also be regulated by administering … an agent effective to modulate the amount of clusterin expression.”

The abstract adds that “such inhibition is significant because bcl-xL is known to act as an inhibitor of apoptosis.”

Title: Cctra Gene as a Tool to Produce Male-Only Progeny in the Mediterranean Fruitfly Ceratitis capitata. Number: 20040082032. Filed: Sept. 8, 2003 (PCT Filed: March 8, 2002). Lead Inventor: Pasquale Delli Bovi, Università di Napoli.

According to the patent application’s abstract, the invention”refers to the identification of the Cctra gene and to corresponding dsRNA molecules comprising Cctra gene sequences as a tool to produce only-male progeny in the Mediterranean fruitfly Ceratitis capitata.


The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.